GAMMA Investing LLC increased its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 175.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,645 shares of the biopharmaceutical company’s stock after purchasing an additional 1,685 shares during the period. GAMMA Investing LLC’s holdings in Dynavax Technologies were worth $29,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also recently modified their holdings of DVAX. Vanguard Group Inc. increased its stake in Dynavax Technologies by 1.4% during the 4th quarter. Vanguard Group Inc. now owns 9,275,788 shares of the biopharmaceutical company’s stock worth $129,676,000 after buying an additional 128,897 shares in the last quarter. Congress Asset Management Co. MA increased its position in shares of Dynavax Technologies by 1.3% during the first quarter. Congress Asset Management Co. MA now owns 229,980 shares of the biopharmaceutical company’s stock worth $2,854,000 after purchasing an additional 2,845 shares in the last quarter. Diversified Trust Co raised its stake in Dynavax Technologies by 3.2% in the 1st quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company’s stock valued at $367,000 after purchasing an additional 925 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in Dynavax Technologies by 19.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 140,622 shares of the biopharmaceutical company’s stock valued at $1,745,000 after purchasing an additional 22,548 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in Dynavax Technologies by 4.2% during the 1st quarter. Principal Financial Group Inc. now owns 767,909 shares of the biopharmaceutical company’s stock worth $9,530,000 after purchasing an additional 31,002 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.
Dynavax Technologies Stock Up 0.3 %
Shares of NASDAQ:DVAX opened at $10.95 on Friday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.15. The stock has a market cap of $1.43 billion, a P/E ratio of 182.50 and a beta of 1.37. The business has a fifty day moving average of $11.05 and a two-hundred day moving average of $11.27. The company has a quick ratio of 13.18, a current ratio of 14.18 and a debt-to-equity ratio of 0.35.
Wall Street Analyst Weigh In
DVAX has been the subject of a number of recent research reports. The Goldman Sachs Group reduced their target price on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.67.
Read Our Latest Analysis on Dynavax Technologies
Dynavax Technologies Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Recommended Stories
- Five stocks we like better than Dynavax Technologies
- What is the Dogs of the Dow Strategy? Overview and Examples
- Survey Reveals: America’s Most Coveted Businesses in 2024
- Pros And Cons Of Monthly Dividend Stocks
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Stock Dividend Cuts Happen Are You Ready?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX – Free Report).
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.